This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Wall Street Analysts Predict a 31.8% Upside in Option Care (OPCH): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.8% in Option Care (OPCH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Should Value Investors Buy Option Care Health (OPCH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Option Care (OPCH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 7.14% and 4.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -1.26% and 1.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include J.Jill, Option Care Health and Amphenol
by Zacks Equity Research
J.Jill, Option Care Health and Amphenol have been highlighted in this Screen of The Week article.
3 Stocks Backed by High Efficiency to Boost Portfolio Returns
by Santanu Roy
Invest in stocks of J.Jill (JILL), Option Care Health (OPCH) and Amphenol (APH) to tap their high-efficiency levels.
New Strong Buy Stocks for June 10th
by Zacks Equity Research
NEM, ODP, IMMR, WSM and OPCH have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2024.
Buy These 3 Beaten-Down MedTech Stocks for a Turnaround Soon
by Moumi Mondal
Investing in beaten-down stocks like OPCH, LNTH and HOLX can be profitable for investors in the long term.
Option Care (OPCH) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Option Care (OPCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
by Shaun Pruitt
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.